GLSI Healthcare

Greenwich LifeSciences, Inc.

$15.92-3.28%

Price as of close on Nov 3, 2026 · Financials updated Oct 1, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: United States
Market cap: 233.7M USD
Enterprise value: 224.8M USD

Overall health

Not enough data: too little is reported yet for an overall view

Only 2 of 4 categories have enough reported data; an overall score needs at least 3.

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 14% from December 2022 to July 2026.
Greenwich LifeSciences had 14% more shares at July 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Greenwich LifeSciences had 14% more shares at July 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Greenwich LifeSciences looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Not profitable yet. Reported a loss in the 12 months to June 2026.
Greenwich LifeSciences reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.
More volatile share price. Beta 1.46: tends to move more than the market.
Greenwich LifeSciences's shares have swung more with the market than most peers' (beta 1.46, above the market's 1.0).

StockQuotient Score

—

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-9.6%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-10.1%

Yahoo Finance fallback · SEC enterprise value unavailable (debt or EBITDA not reported in standard form) · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-5.3%

Yahoo Finance fallback · SEC cash flow or share count unavailable · trailing 12 months · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield1.3%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

Insufficient data

Insufficient data: 1 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.

Profitability

Does it earn well?

Insufficient data

Insufficient data: 1 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.

Risk

Debt, liquidity, price swings

Higher

Higher relative risk

2/3 inputs reported · Partial data

Since last quarter: No major change

Why

Weaker than most peers on:

▼ Beta
▼ Current ratio

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta1.46

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -2.48Sector median: 0.6250 · MAD: 0.3380

Current ratio1.54×

SEC filings · latest balance sheetReported value33% base weight · Z-score -0.75Sector median: 2.5860 · MAD: 1.3850

Debt / equityUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Greenwich LifeSciences

Is Greenwich LifeSciences getting weaker?: Its latest SEC filing (Aug 11, 2026) showed no major changes.
How is Greenwich LifeSciences valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -9.6% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -9.6% vs peers 1.5% (weaker than 100% of peers).
Is Greenwich LifeSciences growing?: Insufficient data: 1 of 3 inputs reported (at least 2 needed).
How profitable is Greenwich LifeSciences?: Insufficient data: 1 of 3 inputs reported (at least 2 needed).
How risky is Greenwich LifeSciences?: Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Beta 1.46 vs a peer median of 0.63 (weaker than 86% of peers).Beta 1.46 vs peers 0.63 (weaker than 86% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 11, 2026 · compared with the quarter ended Mar 31, 2026

No major changes

	Previous quarter	Latest quarter	Change
Net income (12 months)	−22.3M USD	−22.5M USD	+0.9%
Cash	10.5M USD	8.9M USD	−15.5%
Shares outstanding	14.7M	14.7M	0.0%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Biotechnology · 132 companies

Valuations in Biotechnology are within their usual range since 2016.

48% of months since 2016 were valued lower than now.
22% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +530% vs the whole market, against a usual +637%.

2016Shaded: most expensive fifth of its range2026

Earnings-based measures are left out for now because many companies in Biotechnology are losing money.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Return on assets (ROA)	-16.8%	-58.1%	-127.1%	-425.4%	-313.3%	▲ 112 pts
Return on equity (ROE)	-17.0%	-59.2%	-132.7%	-1916.5%	-5480.5%	▼ >999 pts
Current ratio	—	—	—	1.28×	1.06×	▼ 17%

GLSI price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Worth knowing

Shareholders being diluted. Shares outstanding up 14% from December 2022 to July 2026.

Greenwich LifeSciences had 14% more shares at July 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Greenwich LifeSciences had 14% more shares at July 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, Greenwich LifeSciences looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Not profitable yet. Reported a loss in the 12 months to June 2026.

Greenwich LifeSciences reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

More volatile share price. Beta 1.46: tends to move more than the market.

Greenwich LifeSciences's shares have swung more with the market than most peers' (beta 1.46, above the market's 1.0).

Questions investors ask about Greenwich LifeSciences

Is Greenwich LifeSciences getting weaker?

Its latest SEC filing (Aug 11, 2026) showed no major changes.

How is Greenwich LifeSciences valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -9.6% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -9.6% vs peers 1.5% (weaker than 100% of peers).

Is Greenwich LifeSciences growing?

Insufficient data: 1 of 3 inputs reported (at least 2 needed).

How profitable is Greenwich LifeSciences?

Insufficient data: 1 of 3 inputs reported (at least 2 needed).

How risky is Greenwich LifeSciences?

Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Beta 1.46 vs a peer median of 0.63 (weaker than 86% of peers).Beta 1.46 vs peers 0.63 (weaker than 86% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Net income (12 months)

−22.3M USD

−22.5M USD

+0.9%

Cash

10.5M USD

8.9M USD

−15.5%

Shares outstanding

14.7M

14.7M

0.0%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Return on assets (ROA)

-16.8%

-58.1%

-127.1%

-425.4%

-313.3%

▲ 112 pts

Return on equity (ROE)

-17.0%

-59.2%

-132.7%

-1916.5%

-5480.5%

▼ >999 pts

Current ratio

—

1.28×

1.06×

▼ 17%